Efficacy and Safety of Salonsip Compared to Sabiá Plaster (SAL-SIP-03/09)

Hisamitsu Pharmaceutical

Status and phase: Unknown; Phase 3

Conditions: Tendonitis; Myalgia; Contusions; Sprains; Pain

Treatments: Drug: Sabia plaster; Drug: Salonsip plaster

Study type: Interventional

Funder types: Industry

Identifiers

NCT00970658

SAL-SIP-03/09

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy in reducing signs and symptoms in patients with contusions, sprains, muscular injuries and injuries with less than 24 hours early or holders of myalgia, pain and tendonitis in regions miofasciais articulated with Salonsip compared to Sabiá plaster.

It is clinical, open, multicenter, randomized, prospective and comparative, with patients entering at random.

Patients will be included in sufficient quantity to achieve the minimum number of 70 evaluable patients.

Enrollment: 70 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both sexes, of any race, aged 12 years;
• Ability to read, understand and sign the Consent Form, in the case of children under age monitoring and consent of the person responsible;
• Clinical diagnosis of bruises, sprains, trauma, muscle damage occurring in times less than 24 hours or myalgia, pain miofasciais or tendonitis.
• Patients able to understand and maintain the clinical protocol

Exclusion criteria

• Known hypersensitivity to components of the formulas of both the product and the comparative test.
• Known hypersensitivity to paracetamol.
• Location of the lesion with skin wound or irritated.
• Hepatic or renal diseases known.
• Pregnant or breastfeeding.
• Patients who require surgery or immobilization rigid;
• Patients with fractures or rupture of the ligaments.
• Patients in use of anticoagulants.
• Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart disease, hematological diseases, convulsive disorders, autoimmune diseases, renal failure, infections, hormonal disorders and pulmonary disorders.
• History of alcoholism or use of illicit drugs;
• Use of non-steroidal anti-inflammatory drugs, corticosteroids or venoterápicos, topics or any other form of administration.
• Conditions which in the opinion of the investigator makes the patient unsuitable to participate in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

70 participants in 2 patient groups

Salonsip

Experimental group

Description:

The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).

Treatment:

Drug: Salonsip plaster

Sabiá

Active Comparator group

Description:

The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).

Treatment:

Drug: Sabia plaster